Grigoriadis D E, De Souza E B
Neuropeptide Unit, National Institute on Drug Abuse Addiction Research Center, Baltimore, Maryland 21224.
J Biol Chem. 1988 Aug 5;263(22):10927-31.
The ligand binding subunits of the corticotropin-releasing factor (CRF) receptors in brain and anterior pituitary of a number of species have been identified by chemical affinity cross-linking using the homobifunctional cross-linking agent disuccinimidyl suberate and 125I-Tyr0-oCRF (ovine CRF). In homogenates of rat, monkey, and human cerebral cortex, 125I-Tyr0-oCRF was covalently incorporated into a protein of Mr = 58,000. Under identical conditions in the anterior pituitary of rat, monkey, cow, and pig, 125I-Tyr0-oCRF was incorporated into a protein of apparent Mr = 75,000. The specificity of the labeling was typical of the CRF binding site since both the cerebral cortex- and pituitary-labeled proteins exhibited the appropriate pharmacological rank order profile characteristic of the CRF receptor (Nle21,Tyr32-oCRF approximately equal to rat/human CRF approximately equal to ovine CRF approximately equal to alpha-helical CRF(6-41) greater than alpha-helical oCRF(9-41) greater than or equal to oCRF(7-41) greater than rat/human CRF(1-20) approximately equal to vasoactive intestinal peptide). In addition to the major labeled proteins, 125I-Tyr0-oCRF was incorporated into higher molecular weight peptides which may represent precursors and into lower molecular weight components which may represent fragments of the major labeled proteins or altered forms of the CRF binding subunit. In summary, these data indicate a heterogeneity between brain and pituitary CRF receptors with the ligand binding subunit of the brain CRF receptor residing on a Mr = 58,000 protein, while in the anterior pituitary, the identical binding subunit resides on a protein of apparent Mr = 75,000.
通过使用同双功能交联剂辛二酸二琥珀酰亚胺酯和125I-Tyr0-oCRF(羊促肾上腺皮质激素释放因子)进行化学亲和交联,已鉴定出多种物种大脑和垂体前叶中促肾上腺皮质激素释放因子(CRF)受体的配体结合亚基。在大鼠、猴子和人类大脑皮层匀浆中,125I-Tyr0-oCRF共价结合到一个分子量为58,000的蛋白质上。在相同条件下,在大鼠、猴子、牛和猪的垂体前叶中,125I-Tyr0-oCRF结合到一个表观分子量为75,000的蛋白质上。标记的特异性是CRF结合位点的典型特征,因为大脑皮层和垂体标记的蛋白质都表现出CRF受体特有的药理学活性顺序特征(Nle21,Tyr32-oCRF约等于大鼠/人类CRF约等于羊CRF约等于α-螺旋CRF(6-41)大于α-螺旋羊CRF(9-41)大于或等于羊CRF(7-41)大于大鼠/人类CRF(1-20)约等于血管活性肠肽)。除了主要的标记蛋白质外,125I-Tyr0-oCRF还结合到可能代表前体的高分子量肽以及可能代表主要标记蛋白质片段或CRF结合亚基改变形式的低分子量组分中。总之,这些数据表明大脑和垂体CRF受体之间存在异质性,大脑CRF受体的配体结合亚基存在于一个分子量为58,000的蛋白质上,而在垂体前叶中,相同的结合亚基存在于一个表观分子量为75,000的蛋白质上。